8-K: Zymeworks Announces Second Quarter 2024 Financial Results and Corporate Update

Zymeworks reported $395.9 million in cash resources and provided updates on its clinical programs, including regulatory milestones for zanidatamab and the advancement of new drug candidates.

Summary

• Zymeworks announced its financial results for the second quarter of 2024, reporting $29.3 million in revenue for the first six months of 2024, compared to $42.6 million for the same period in 2023.
• The company's research and development expenses decreased to $61.2 million for the first six months of 2024, down from $85.3 million in 2023, primarily due to the transfer of the zanidatamab program to Jazz Pharmaceuticals.
• Zymeworks reported a net loss of $69.3 million for the first six months of 2024, compared to a $75.5 million loss for the same period in 2023.
• As of June 30, 2024, Zymeworks had $395.9 million in cash resources, which, combined with anticipated regulatory milestone payments, is expected to fund operations into the second half of 2027.
• The company received an $8 million milestone payment from BeiGene following the acceptance of the zanidatamab BLA in China.
• The FDA granted Priority Review for the zanidatamab BLA for biliary tract cancer with a target action date of November 29, 2024.
• Zymeworks discontinued the clinical development of zanidatamab zovodotin to focus on early-stage programs like ZW171 and ZW191.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the strong cash position, regulatory progress with zanidatamab, and advancement of the wholly-owned pipeline. However, the decrease in revenue and the impairment charge temper the overall optimism.

Positives

• Zymeworks has a strong cash position of $395.9 million, providing a cash runway into the second half of 2027.
• The FDA granted Priority Review for zanidatamab, indicating a potentially faster approval process.
• The acceptance of the zanidatamab BLA in China triggered an $8 million milestone payment.
• The company is advancing its wholly-owned pipeline with IND clearances for ZW171 and ZW191.
• Positive overall survival data for zanidatamab in biliary tract cancer was presented at ASCO.
• The company is actively progressing regulatory permission to commence clinical studies for ZW171 and ZW191 in non-US jurisdictions in the second half of 2024.

Negatives

• Revenue decreased to $29.3 million for the first six months of 2024, compared to $42.6 million for the same period in 2023.
• The company recorded a non-cash impairment charge of $17.3 million due to the discontinuation of the zanidatamab zovodotin program.
• The net loss for the first six months of 2024 was $69.3 million, although this is an improvement from the $75.5 million loss in the same period of 2023.

Risks

• Clinical trials for Zymeworks' product candidates may not demonstrate safety and efficacy.
• Regulatory agencies may impose additional requirements or delay the initiation of clinical trials.
• The company may not achieve milestones or receive additional payments under its collaborations.
• The company's assumptions and estimates regarding its financial condition and cash runway may be incorrect.
• Zymeworks may be unable to maintain or enter into new partnerships or strategic collaborations.

Future Outlook

Zymeworks expects its existing cash resources, combined with anticipated regulatory milestone payments, to fund planned operations into the second half of 2027. The company plans to initiate Phase 1 dose escalation studies for ZW171 and ZW191 in the second half of 2024 and file INDs for ZW220 and ZW251 in 2025.

Management Comments

• Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks, stated that they have made significant progress in their wholly-owned portfolio and secured FDA clearance for Phase 1 clinical trials for ZW171 and ZW191.
• Mr. Galbraith also noted that recent overall survival findings from the Phase 2b HERIZON-BTC-01 clinical trial validate their protein engineering capabilities and the potential for zanidatamab to provide a clinically meaningful option for patients with BTC.
• Paul Moore, Ph.D., Chief Scientific Officer at Zymeworks, stated that receiving FDA clearance for IND submissions for ZW171 and ZW191 represents a critical step forward in their mission to develop innovative treatments.

Industry Context

This announcement reflects the ongoing progress in the biotechnology sector, particularly in the development of novel cancer therapies. The focus on bispecific antibodies and antibody-drug conjugates aligns with current trends in oncology drug development. The collaboration with Jazz and BeiGene highlights the importance of strategic partnerships in bringing new therapies to market.

Comparison to Industry Standards

• Zymeworks' reported cash runway into 2H 2027 is a positive sign, indicating financial stability compared to many other clinical-stage biotech companies that often face near-term funding concerns.
• The Priority Review granted by the FDA for zanidatamab is a significant milestone, potentially accelerating its approval timeline, which is a competitive advantage in the oncology space.
• The median overall survival of 15.5 months for zanidatamab in HER2+ BTC patients is promising, and compares favorably to historical outcomes for this patient population, although direct comparisons to other specific therapies would require further analysis.
• The discontinuation of the zanidatamab zovodotin program is a strategic decision to focus on more promising early-stage assets, a common practice in the biotech industry to optimize resource allocation.
• The initiation of Phase 3 trials by Jazz for zanidatamab in breast cancer demonstrates the potential of the drug in multiple indications, similar to other successful oncology drugs that have expanded their use beyond initial approvals.

Management Changes

Related Party Transactions

• Zymeworks received $20.7 million in development support and drug supply revenue from Jazz.
• Zymeworks received $8.0 million of milestone revenue from BeiGene in relation to the acceptance by the CDE of the NMPA in China of the BLA for zanidatamab for 2L treatment of HER2-positive BTC.
• Zymeworks received $0.4 million from BeiGene for research support payments.
• Zymeworks received $0.2 million from partners for research support and other payments.

Stakeholder Impact

• Shareholders will be impacted by the financial results and the progress of the clinical programs.
• Employees will be affected by the strategic decisions and the company's financial performance.
• Patients with HER2-positive cancers may benefit from the development of zanidatamab and other product candidates.
• Partners like Jazz and BeiGene will be impacted by the progress of the collaboration agreements.

Next Steps

• Initiate Phase 1 dose escalation studies for ZW171 and ZW191 in the second half of 2024.
• Progress regulatory permission to commence clinical studies for ZW171 and ZW191 in non-US jurisdictions.
• Continue IND-enabling studies for ZW220 and ZW251, with IND filings scheduled for 2025.
• Continue to track events in the HERIZON-GEA-01 trial, with top-line progression-free survival data expected in 2Q25.

Key Dates

Keywords

Zymeworks, zanidatamab, biologics, cancer, clinical trials, FDA, milestone payments, HER2, biliary tract cancer, antibody-drug conjugate, bispecific antibody, ZW171, ZW191, BeiGene, Jazz Pharmaceuticals